These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 25691428)

  • 21. Development of mavoglurant and its potential for the treatment of fragile X syndrome.
    Gomez-Mancilla B; Berry-Kravis E; Hagerman R; von Raison F; Apostol G; Ufer M; Gasparini F; Jacquemont S
    Expert Opin Investig Drugs; 2014 Jan; 23(1):125-34. PubMed ID: 24251408
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Metabotropic glutamate receptor 5 as drug target for Fragile X syndrome.
    Scharf SH; Jaeschke G; Wettstein JG; Lindemann L
    Curr Opin Pharmacol; 2015 Feb; 20():124-34. PubMed ID: 25488569
    [TBL] [Abstract][Full Text] [Related]  

  • 23. PDE-4 inhibition rescues aberrant synaptic plasticity in Drosophila and mouse models of fragile X syndrome.
    Choi CH; Schoenfeld BP; Weisz ED; Bell AJ; Chambers DB; Hinchey J; Choi RJ; Hinchey P; Kollaros M; Gertner MJ; Ferrick NJ; Terlizzi AM; Yohn N; Koenigsberg E; Liebelt DA; Zukin RS; Woo NH; Tranfaglia MR; Louneva N; Arnold SE; Siegel SJ; Bolduc FV; McDonald TV; Jongens TA; McBride SM
    J Neurosci; 2015 Jan; 35(1):396-408. PubMed ID: 25568131
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Biomedical research. A fix for fragile X syndrome?
    Miller G
    Science; 2006 Apr; 312(5773):521. PubMed ID: 16645065
    [No Abstract]   [Full Text] [Related]  

  • 25. Emerging pharmacological therapies in fragile X syndrome and autism.
    Yamasue H; Aran A; Berry-Kravis E
    Curr Opin Neurol; 2019 Aug; 32(4):635-640. PubMed ID: 31045620
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Brief review of current research in FXS: implications for treatment with psychotropic medication.
    Valdovinos MG
    Res Dev Disabil; 2007; 28(6):539-45. PubMed ID: 17034990
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A phase 1/2, open-label assessment of the safety, tolerability, and efficacy of transdermal cannabidiol (ZYN002) for the treatment of pediatric fragile X syndrome.
    Heussler H; Cohen J; Silove N; Tich N; Bonn-Miller MO; Du W; O'Neill C; Sebree T
    J Neurodev Disord; 2019 Aug; 11(1):16. PubMed ID: 31370779
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Fragile X Syndrome: from molecular pathology to therapy.
    Maurin T; Zongaro S; Bardoni B
    Neurosci Biobehav Rev; 2014 Oct; 46 Pt 2():242-55. PubMed ID: 24462888
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Translation Inhibition by Rocaglates Is Independent of eIF4E Phosphorylation Status.
    Chu J; Cencic R; Wang W; Porco JA; Pelletier J
    Mol Cancer Ther; 2016 Jan; 15(1):136-41. PubMed ID: 26586722
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Acamprosate rescues neuronal defects in the Drosophila model of Fragile X Syndrome.
    Hutson RL; Thompson RL; Bantel AP; Tessier CR
    Life Sci; 2018 Feb; 195():65-70. PubMed ID: 29317220
    [TBL] [Abstract][Full Text] [Related]  

  • 31. High-Throughput Screening Using iPSC-Derived Neuronal Progenitors to Identify Compounds Counteracting Epigenetic Gene Silencing in Fragile X Syndrome.
    Kaufmann M; Schuffenhauer A; Fruh I; Klein J; Thiemeyer A; Rigo P; Gomez-Mancilla B; Heidinger-Millot V; Bouwmeester T; Schopfer U; Mueller M; Fodor BD; Cobos-Correa A
    J Biomol Screen; 2015 Oct; 20(9):1101-11. PubMed ID: 26024946
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Fragile X syndrome: From protein function to therapy.
    Bagni C; Oostra BA
    Am J Med Genet A; 2013 Nov; 161A(11):2809-21. PubMed ID: 24115651
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effect of lovastatin on behavior in children and adults with fragile X syndrome: an open-label study.
    Çaku A; Pellerin D; Bouvier P; Riou E; Corbin F
    Am J Med Genet A; 2014 Nov; 164A(11):2834-42. PubMed ID: 25258112
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Translational endpoints in fragile X syndrome.
    de Esch CE; Zeidler S; Willemsen R
    Neurosci Biobehav Rev; 2014 Oct; 46 Pt 2():256-69. PubMed ID: 24184744
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [eIF4E and developmental decisions: when translation drives the development].
    Oulhen N; Cormier P
    Med Sci (Paris); 2006 May; 22(5):507-13. PubMed ID: 16687119
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Autism Symptoms in Fragile X Syndrome.
    Niu M; Han Y; Dy ABC; Du J; Jin H; Qin J; Zhang J; Li Q; Hagerman RJ
    J Child Neurol; 2017 Sep; 32(10):903-909. PubMed ID: 28617074
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Disruption of GpI mGluR-Dependent Cav2.3 Translation in a Mouse Model of Fragile X Syndrome.
    Gray EE; Murphy JG; Liu Y; Trang I; Tabor GT; Lin L; Hoffman DA
    J Neurosci; 2019 Sep; 39(38):7453-7464. PubMed ID: 31350260
    [TBL] [Abstract][Full Text] [Related]  

  • 38. eIF4E/Fmr1 double mutant mice display cognitive impairment in addition to ASD-like behaviors.
    Huynh TN; Shah M; Koo SY; Faraud KS; Santini E; Klann E
    Neurobiol Dis; 2015 Nov; 83():67-74. PubMed ID: 26306459
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The neurochemical basis for the treatment of autism spectrum disorders and Fragile X Syndrome.
    Hampson DR; Adusei DC; Pacey LK
    Biochem Pharmacol; 2011 May; 81(9):1078-86. PubMed ID: 21333634
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Down Syndrome and Fragile X Syndrome in a Colombian Woman: Case Report.
    Saldarriaga W; Ruiz FA; Tassone F; Hagerman R
    J Appl Res Intellect Disabil; 2017 Sep; 30(5):970-974. PubMed ID: 27456465
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.